Update on second primary malignancies in multiple myeloma: A focused review

O. Landgren, S. Mailankody

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

The last decade has seen significant advances in the management of patients with multiple myeloma (MM). With increasingly effective therapies, MM patients are living longer. With improvements in survival, long-term complications including second primary malignancies are becoming new challenges in providing optimal care for MM patients. Three randomized studies have demonstrated possible clinical benefit with maintenance lenalidomide for patients with MM. These same studies have also demonstrated an increased risk of second primary malignancies. In this review, we will update on the current information regarding mechanisms and risk of developing second primary malignancies with a particular focus on disease-and treatment-related factors.

Original languageEnglish (US)
Pages (from-to)1423-1426
Number of pages4
JournalLeukemia
Volume28
Issue number7
DOIs
StatePublished - Jul 2014
Externally publishedYes

Keywords

  • acute myeloid leukemia
  • lenalidomide
  • multiple myeloma
  • myelodysplastic syndromes
  • secondary malignancy
  • treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Update on second primary malignancies in multiple myeloma: A focused review'. Together they form a unique fingerprint.

Cite this